Publications by authors named "G Fatti"
Objective: We studied the transition to dolutegravir-containing antiretroviral therapy (ART) at HIV treatment clinics within the International epidemiology Databases to Evaluate AIDS (IeDEA).
Design: Site-level survey conducted in 2020-2021 among HIV clinics in low- and middle-income countries (LMICs).
Methods: We assessed the status of dolutegravir rollout and viral load and drug resistance testing practices for persons on ART switching to dolutegravir-based regimens.
Background: Periods of droughts can lead to decreased food security, and altered behaviours, potentially affecting outcomes on antiretroviral therapy (ART) among persons with HIV (PWH). We investigated whether decreased rainfall is associated with adverse outcomes among PWH on ART in Southern Africa.
Methods: Data were combined from 11 clinical cohorts of PWH in Lesotho, Malawi, Mozambique, South Africa, Zambia, and Zimbabwe, participating in the International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration.
Triboelectrification mechanism is still not understood, despite centuries of investigations. Here, we propose a model showing that mechanochemistry is key to elucidate triboelectrification fundamental properties. Studying contact between gold and silicate glasses, we observe that the experimental triboelectric output is subject to large variations and polarity inversions.
View Article and Find Full Text PDFArticle Synopsis
- Despite progress in HIV care in South Africa, a significant number of patients still present with Advanced HIV Disease (AHD), with a pooled prevalence of 43.45% among ART-naive and 58.6% among ART-experienced patients.
- A systematic review of studies from 2010 to 2022 identified 53 qualifying studies, involving over 11.5 million individuals, but showed high variability in results, indicating caution in interpreting the pooled data.
- The findings underline the necessity for regular CD4 cell count monitoring and the development of effective support systems to help ART patients maintain their treatment, as the AHD burden remains substantial.
Background: WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose <3 months of age, and data in neonates are limited.
Methods: We included infants who initiated ART aged <3 months, between 2006 and 2019, in nine South African cohorts.